Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 214

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

Open access
Voss, Martin H., Hakimi, A. Ari, Pham, Can G., Brannon, A. Rose, Chen, Ying-Bei, Cunha, Luis F., Akin, Oguz, Liu, Han, Takeda, Shugaku, Scott, Sasinya N., Socci, Nicholas D., Viale, Agnes, Schultz, Nikolaus, Sander, Chris, Reuter, Victor E., Russo, Paul, Cheng, Emily H., Motzer, Robert J., Berger, Michael F., Hsieh, James J.·2014·Clinical Cancer Research

Abstract

Purpose: Rapalogs are allosteric mTOR inhibitors and approved agents for advanced kidney cancer. Reports of clonal heterogeneity in this disease challenge the concept of targeted monotherapy, yet a small subset of patients derives extended benefit. Our aim was to analyze such outliers and explore the genomic background of extreme rapalog sensitivity in the context of intratumor heterogeneity. Experimental Design: We analyzed archived tumor tissue of 5 patients with renal cell carcinoma, who previously achieved durable disease control with rapalogs (median duration, 28 months). DNA was extracted from spatially separate areas of primary tumors and metastases. Custom target capture and ultradeep sequencing was used to identify alterations across 230 target genes. Whole-exome sequence analysis was added to investigate genes beyond this original target list. Results: Five long-term responders contributed 14 specimens to explore clonal heterogeneity. Genomic alterations with activating effect on mTOR signaling were detected in 11 of 14 specimens, offering plausible explanation for exceptional treatment response through alterations in two genes (TSC1 and MTOR). In two subjects, distinct yet functionally convergent alterations activated the mTOR pathway in spatially separate sites. In 1 patient, concurrent genomic events occurred in two separate pathway components across different tumor regions. Conclusions: Analysis of outlier cases can facilitate identification of potential biomarkers for targeted agents, and we implicate two genes as candidates for further study in this class of drugs. The previously reported phenomenon of clonal convergence can occur within a targetable pathway which might have implications for biomarker development beyond this disease and this class of agents. Clin Cancer Res; 20(7); 1955–64. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-2345

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 214

Metadata

Authors
Voss, M. H., Hakimi, A. A., Pham, C. G., Brannon, A. R., Chen, Y.-B., Cunha, L. F., Akin, O., Liu, H., Takeda, S., Scott, S. N., Socci, N. D., Viale, A., Schultz, N., Sander, C., Reuter, V. E., Russo, P., Cheng, E. H., Motzer, R. J., Berger, M. F., & Hsieh, J. J.
Venue
Clinical Cancer Research
Published
2014-03-31
Volume
20
Issue
7
Pages
1955-1964
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2148424438
Cited by
214
References
6
FWCI
25.93
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-2345
The paper
Voss, M. H., Hakimi, A. A., Pham, C. G., Brannon, A. R., Chen, Y.-B., Cunha, L. F., Akin, O., Liu, H., Takeda, S., Scott, S. N., Socci, N. D., Viale, A., Schultz, N., Sander, C., Reuter, V. E., Russo, P., Cheng, E. H., Motzer, R. J., Berger, M. F., & Hsieh, J. J. (2014). Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-2345

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.